Survival analysis in patients with T315I BCR-ABL mutation. (A) OS from leukemia diagnosis by disease phases at the time of leukemia diagnosis. (B) OS from TKI treatment start by disease phase at the time of TKI treatment start. (C) OS from first TKI resistance by disease phase at the time of first TKI resistance. (D) OS from first T315I mutation detection by disease phase at the time of T315I mutation detection. (E) OS from first T315I mutation detection by disease phase at the time of T315I mutation detection, where CML LBP were combined with Ph⁺ ALL (n = 214)